MedPath
Found 452 clinical trials|View Analysis
Sort by:
Need a comprehensive medical report on "RNA"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals

Small RNA Pathways in Mammalian Gametogenesis

Completed
Conditions
Male Infertility
First Posted Date
2016-08-12
Last Posted Date
2024-07-19
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
182
Registration Number
NCT02864329
Locations
🇺🇸

Weill Cornell Medicine, New York, New York, United States

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

Phase 3
Completed
Conditions
Urothelial Carcinoma Associated 1 RNA, Human
Interventions
Biological: Pembrolizumab
First Posted Date
2016-08-02
Last Posted Date
2023-09-08
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1010
Registration Number
NCT02853305

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Terminated
Conditions
Hormone-Resistant Prostate Cancer
Prostate Adenocarcinoma
Metastatic Prostate Carcinoma
Interventions
Other: Cytology Specimen Collection Procedure
Other: Laboratory Biomarker Analysis
First Posted Date
2016-08-02
Last Posted Date
2021-04-05
Lead Sponsor
University of Southern California
Target Recruit Count
7
Registration Number
NCT02853097
Locations
🇺🇸

Los Angeles County-USC Medical Center, Los Angeles, California, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Keck Medical Center of USC Pasadena, Pasadena, California, United States

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

Phase 2
Completed
Conditions
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Interventions
Biological: FluLaval® Tetra (15 µg/strain)
Biological: 60 µg/strain of Quadrivalent VLP Vaccine
Biological: 30 µg/strain of Quadrivalent VLP Vaccine
Biological: Fluzone® High-Dose (60 µg/strain)
First Posted Date
2016-07-13
Last Posted Date
2019-10-25
Lead Sponsor
Medicago
Target Recruit Count
1001
Registration Number
NCT02831751
Locations
🇺🇸

Paradigm Research - Redding, Redding, California, United States

🇺🇸

Broward Research Group (BRG), Hollywood, Florida, United States

🇺🇸

Miami Research Associates (MRA), South Miami, Florida, United States

and more 12 locations

Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms

Completed
Conditions
Polycythemia Vera
Essential Thrombocythemia
Interventions
Biological: RNA sample of total leukocytes before start of treatment
First Posted Date
2016-07-06
Last Posted Date
2020-06-19
Lead Sponsor
University Hospital, Bordeaux
Target Recruit Count
148
Registration Number
NCT02823184
Locations
🇫🇷

Chu Angers, Angers, France

🇫🇷

Ch de La Cöte Basque, Bayonne, France

🇫🇷

Ch de Dax, DAX, France

and more 4 locations

Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa

Not Applicable
Completed
Conditions
HIV
AIDS
Interventions
Procedure: HIV-1 RNA Resistance Testing
First Posted Date
2016-06-01
Last Posted Date
2023-03-21
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
840
Registration Number
NCT02787499
Locations
🇺🇬

Mbarara University of Science and Technology, Mbarara, Uganda

🇿🇦

University of Kwa-Zulu Natal, Durban, South Africa

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

Phase 2
Completed
Conditions
RNA Virus Infections
Respiratory Tract Diseases
Virus Diseases
Respiratory Tract Infections
Interventions
Biological: 30 µg/strain of Quadrivalent VLP Vaccine
Biological: 15 µg/strain of Quadrivalent VLP Vaccine
Biological: 15 µg/strain of the licensed quadrivalent vaccine
First Posted Date
2016-05-11
Last Posted Date
2020-06-11
Lead Sponsor
Medicago
Target Recruit Count
900
Registration Number
NCT02768805
Locations
🇨🇦

Équipe de recherche en vaccination du CHU de Québec-Université Laval (CHU), Quebec, Canada

🇨🇦

McGill University Health Center - Vaccine Study Center (MUHC), Pierrefonds, Quebec, Canada

🇨🇦

Diex Research Montreal, Montreal, Quebec, Canada

and more 6 locations

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru

Not Applicable
Completed
Conditions
RNA Virus Infections
Acquired Immunodeficiency Syndrome
Sexually Transmitted Diseases
Retroviridae Infections
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Infections
Lentivirus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Interventions
Procedure: Circumcision
Procedure: Flexible sigmoidoscopy
First Posted Date
2015-12-15
Last Posted Date
2015-12-15
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
29
Registration Number
NCT02630082

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

Early Phase 1
Terminated
Conditions
Hodgkin Lymphoma
Interventions
Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)
First Posted Date
2015-12-08
Last Posted Date
2020-05-21
Lead Sponsor
University of Pennsylvania
Target Recruit Count
2
Registration Number
NCT02624258
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

Phase 2
Terminated
Conditions
Hepatitis C
Hepatitis, Viral, Human
Liver Diseases
Hepatitis
RNA Virus Infections
Digestive System Diseases
Flaviviridae Infections
Virus Diseases
Interventions
First Posted Date
2015-11-24
Last Posted Date
2024-05-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
94
Registration Number
NCT02613403
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy